INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8501, 29838, 'Mirtazapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8502, 33212, 'Mirtazapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8503, 8238, 'Mirtazapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tetracyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tetracyclic antidepressants are not approved for use in bipolar depression.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8504, 9826, 'Mirtazapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tetracyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tetracyclic antidepressants are not approved for use in bipolar depression.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8505, 13087, 'Mirtazapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tetracyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tetracyclic antidepressants are not approved for use in bipolar depression.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8506, 14323, 'Mirtazapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tetracyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tetracyclic antidepressants are not approved for use in bipolar depression.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8507, 22839, 'Mirtazapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tetracyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tetracyclic antidepressants are not approved for use in bipolar depression.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8508, 22841, 'Mirtazapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tetracyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tetracyclic antidepressants are not approved for use in bipolar depression.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8509, 25853, 'Mirtazapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tetracyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tetracyclic antidepressants are not approved for use in bipolar depression.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8510, 29838, 'Mirtazapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tetracyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tetracyclic antidepressants are not approved for use in bipolar depression.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8511, 33212, 'Mirtazapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tetracyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tetracyclic antidepressants are not approved for use in bipolar depression.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8512, 8238, 'Mirtazapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8513, 9826, 'Mirtazapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8514, 13087, 'Mirtazapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8515, 14323, 'Mirtazapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8516, 22839, 'Mirtazapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8517, 22841, 'Mirtazapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8518, 25853, 'Mirtazapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8519, 29838, 'Mirtazapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8520, 33212, 'Mirtazapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8521, 8238, 'Mirtazapine', 'Hypotension', 'The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the alpha-1 adrenergic blocking effects of these drugs.  Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8522, 9826, 'Mirtazapine', 'Hypotension', 'The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the alpha-1 adrenergic blocking effects of these drugs.  Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8523, 13087, 'Mirtazapine', 'Hypotension', 'The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the alpha-1 adrenergic blocking effects of these drugs.  Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8524, 14323, 'Mirtazapine', 'Hypotension', 'The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the alpha-1 adrenergic blocking effects of these drugs.  Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8525, 22839, 'Mirtazapine', 'Hypotension', 'The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the alpha-1 adrenergic blocking effects of these drugs.  Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8526, 22841, 'Mirtazapine', 'Hypotension', 'The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the alpha-1 adrenergic blocking effects of these drugs.  Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8527, 25853, 'Mirtazapine', 'Hypotension', 'The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the alpha-1 adrenergic blocking effects of these drugs.  Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8528, 29838, 'Mirtazapine', 'Hypotension', 'The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the alpha-1 adrenergic blocking effects of these drugs.  Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8529, 33212, 'Mirtazapine', 'Hypotension', 'The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the alpha-1 adrenergic blocking effects of these drugs.  Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8530, 8238, 'Mirtazapine', 'Neutropenia', 'The use of tetracyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3) with associated signs and symptoms,( e.g., fever, infection, etc.).  Patients with preexisting neutropenia or agranulocytosis should be monitored closely during therapy for further decreases in white blood cell (WBC) counts.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8531, 9826, 'Mirtazapine', 'Neutropenia', 'The use of tetracyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3) with associated signs and symptoms,( e.g., fever, infection, etc.).  Patients with preexisting neutropenia or agranulocytosis should be monitored closely during therapy for further decreases in white blood cell (WBC) counts.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8532, 13087, 'Mirtazapine', 'Neutropenia', 'The use of tetracyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3) with associated signs and symptoms,( e.g., fever, infection, etc.).  Patients with preexisting neutropenia or agranulocytosis should be monitored closely during therapy for further decreases in white blood cell (WBC) counts.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8533, 14323, 'Mirtazapine', 'Neutropenia', 'The use of tetracyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3) with associated signs and symptoms,( e.g., fever, infection, etc.).  Patients with preexisting neutropenia or agranulocytosis should be monitored closely during therapy for further decreases in white blood cell (WBC) counts.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8534, 22839, 'Mirtazapine', 'Neutropenia', 'The use of tetracyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3) with associated signs and symptoms,( e.g., fever, infection, etc.).  Patients with preexisting neutropenia or agranulocytosis should be monitored closely during therapy for further decreases in white blood cell (WBC) counts.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8535, 22841, 'Mirtazapine', 'Neutropenia', 'The use of tetracyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3) with associated signs and symptoms,( e.g., fever, infection, etc.).  Patients with preexisting neutropenia or agranulocytosis should be monitored closely during therapy for further decreases in white blood cell (WBC) counts.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8536, 25853, 'Mirtazapine', 'Neutropenia', 'The use of tetracyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3) with associated signs and symptoms,( e.g., fever, infection, etc.).  Patients with preexisting neutropenia or agranulocytosis should be monitored closely during therapy for further decreases in white blood cell (WBC) counts.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8537, 29838, 'Mirtazapine', 'Neutropenia', 'The use of tetracyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3) with associated signs and symptoms,( e.g., fever, infection, etc.).  Patients with preexisting neutropenia or agranulocytosis should be monitored closely during therapy for further decreases in white blood cell (WBC) counts.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8538, 33212, 'Mirtazapine', 'Neutropenia', 'The use of tetracyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3) with associated signs and symptoms,( e.g., fever, infection, etc.).  Patients with preexisting neutropenia or agranulocytosis should be monitored closely during therapy for further decreases in white blood cell (WBC) counts.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.', '3', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8539, 8238, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991):  233-6|Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991):  141-4|"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984):  1103-4|Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986):  1482-3|Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987):  423-4|Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991):  275-8|Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987):  274-5|Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986):  787-9|"Product Information. Desyrel (trazodone)." Bristol-Myers Squibb  (2001):|Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993):  s45-50|"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995):  218|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997):  578-9|"Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8540, 9826, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991):  233-6|Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991):  141-4|"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984):  1103-4|Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986):  1482-3|Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987):  423-4|Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991):  275-8|Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987):  274-5|Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986):  787-9|"Product Information. Desyrel (trazodone)." Bristol-Myers Squibb  (2001):|Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993):  s45-50|"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995):  218|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997):  578-9|"Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8541, 13087, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991):  233-6|Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991):  141-4|"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984):  1103-4|Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986):  1482-3|Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987):  423-4|Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991):  275-8|Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987):  274-5|Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986):  787-9|"Product Information. Desyrel (trazodone)." Bristol-Myers Squibb  (2001):|Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993):  s45-50|"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995):  218|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997):  578-9|"Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8542, 14323, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991):  233-6|Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991):  141-4|"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984):  1103-4|Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986):  1482-3|Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987):  423-4|Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991):  275-8|Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987):  274-5|Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986):  787-9|"Product Information. Desyrel (trazodone)." Bristol-Myers Squibb  (2001):|Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993):  s45-50|"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995):  218|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997):  578-9|"Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8543, 22839, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991):  233-6|Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991):  141-4|"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984):  1103-4|Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986):  1482-3|Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987):  423-4|Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991):  275-8|Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987):  274-5|Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986):  787-9|"Product Information. Desyrel (trazodone)." Bristol-Myers Squibb  (2001):|Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993):  s45-50|"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995):  218|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997):  578-9|"Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8544, 22841, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991):  233-6|Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991):  141-4|"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984):  1103-4|Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986):  1482-3|Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987):  423-4|Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991):  275-8|Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987):  274-5|Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986):  787-9|"Product Information. Desyrel (trazodone)." Bristol-Myers Squibb  (2001):|Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993):  s45-50|"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995):  218|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997):  578-9|"Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8545, 25853, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991):  233-6|Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991):  141-4|"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984):  1103-4|Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986):  1482-3|Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987):  423-4|Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991):  275-8|Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987):  274-5|Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986):  787-9|"Product Information. Desyrel (trazodone)." Bristol-Myers Squibb  (2001):|Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993):  s45-50|"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995):  218|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997):  578-9|"Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8546, 29838, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991):  233-6|Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991):  141-4|"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984):  1103-4|Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986):  1482-3|Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987):  423-4|Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991):  275-8|Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987):  274-5|Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986):  787-9|"Product Information. Desyrel (trazodone)." Bristol-Myers Squibb  (2001):|Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993):  s45-50|"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995):  218|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997):  578-9|"Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8547, 33212, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991):  233-6|Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991):  141-4|"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984):  1103-4|Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986):  1482-3|Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987):  423-4|Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991):  275-8|Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987):  274-5|Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986):  787-9|"Product Information. Desyrel (trazodone)." Bristol-Myers Squibb  (2001):|Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993):  s45-50|"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995):  218|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45|Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997):  578-9|"Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8548, 8238, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996):  389-402|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8549, 9826, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996):  389-402|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8550, 13087, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996):  389-402|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8551, 14323, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996):  389-402|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8552, 22839, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996):  389-402|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8553, 22841, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996):  389-402|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8554, 25853, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996):  389-402|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8555, 29838, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996):  389-402|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8556, 33212, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996):  389-402|Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995):  37-45', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8557, 8238, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8558, 9826, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8559, 13087, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8560, 14323, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8561, 22839, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8562, 22841, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8563, 25853, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8564, 29838, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8565, 33212, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8566, 8238, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996):  184-90', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8567, 9826, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996):  184-90', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8568, 13087, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996):  184-90', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8569, 14323, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996):  184-90', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8570, 22839, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996):  184-90', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8571, 22841, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996):  184-90', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8572, 25853, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996):  184-90', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8573, 29838, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996):  184-90', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8574, 33212, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990):  191-6|"Product Information. Remeron (mirtazapine)." Organon  (2001):|Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996):  184-90', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8575, 8238, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8576, 9826, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8577, 13087, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8578, 14323, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8579, 22839, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8580, 22841, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8581, 25853, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8582, 29838, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8583, 33212, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', '"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8584, 229, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8585, 5890, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8586, 7509, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8587, 8215, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8588, 11343, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8589, 13593, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8590, 15379, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8591, 15412, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8592, 19585, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8593, 20186, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8594, 20187, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8595, 20196, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8596, 20197, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8597, 20210, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8598, 20216, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8599, 22799, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8600, 22801, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8601, 22802, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8602, 22803, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8603, 23414, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8604, 24398, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8605, 24743, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8606, 24745, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8607, 25791, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8608, 25792, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8609, 25811, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8610, 25812, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8611, 26586, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8612, 33210, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', '"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8613, 229, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8614, 5890, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8615, 7509, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8616, 8215, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8617, 11343, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8618, 13593, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8619, 15379, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8620, 15412, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8621, 19585, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8622, 20186, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8623, 20187, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8624, 20196, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8625, 20197, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8626, 20210, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8627, 20216, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8628, 22799, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8629, 22801, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8630, 22802, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8631, 22803, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8632, 23414, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8633, 24398, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8634, 24743, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8635, 24745, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8636, 25791, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8637, 25792, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8638, 25811, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8639, 25812, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8640, 26586, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8641, 33210, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'Miller DD, Love DW "Drug therapy reviews: evaluation of minoxidil." Am J Hosp Pharm 37 (1980):  808-14|Bennion SD "Chest pain and abnormal electrocardiogram associated with minoxidil." Mil Med 147 (1982):  367-8|Campese VM "Minoxidil: a review of its pharmacological properties and therapeutic use." Drugs 22 (1981):  257-78|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8642, 229, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8643, 5890, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8644, 7509, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8645, 8215, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8646, 11343, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8647, 13593, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8648, 15379, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8649, 15412, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8650, 19585, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8651, 20186, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8652, 20187, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8653, 20196, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8654, 20197, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8655, 20210, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8656, 20216, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8657, 22799, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8658, 22801, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8659, 22802, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8660, 22803, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8661, 23414, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8662, 24398, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8663, 24743, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8664, 24745, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8665, 25791, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8666, 25792, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8667, 25811, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8668, 25812, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8669, 26586, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8670, 33210, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'Lowenthal DT, Affrime MB "Pharmacology and pharmacokinetics of minoxidil." J Cardiovasc Pharmacol 2 (1980):  s93-106|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8671, 229, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8672, 5890, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8673, 7509, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8674, 8215, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8675, 11343, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8676, 13593, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8677, 15379, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8678, 15412, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8679, 19585, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8680, 20186, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8681, 20187, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8682, 20196, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8683, 20197, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8684, 20210, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8685, 20216, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8686, 22799, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8687, 22801, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8688, 22802, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8689, 22803, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8690, 23414, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8691, 24398, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8692, 24743, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8693, 24745, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8694, 25791, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8695, 25792, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8696, 25811, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8697, 25812, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8698, 26586, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8699, 33210, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'Halstenson CE, Opsahl JA, Wright CE, et al. "Disposition of minoxidil in patients with various degrees of renal function." J Clin Pharmacol 29 (1989):  798-802|Lowenthal DT, Onesti G, Mutterperl R, Affrime M, Martinez EW, Kim KE, Busby P, Shirk J, Swartz C "Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function." J Clin Pharmacol 18 (1978):  500-8|"Product Information. Loniten (minoxidil)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8700, 0, 'Mitomycin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8701, 0, 'Mitomycin', 'Hemorrhagic Disorders', 'The use of mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorders, or an increase in bleeding tendency.  Mitomycin induces cumulative, delayed myelosuppression.  Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy.  Therapy with mitomycin should be withheld if platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.', '3', '"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8702, 0, 'Mitomycin', 'Bone Marrow Failure Disorders', 'Mitomycin induces cumulative, delayed myelosuppression.  Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy.  Anemia occurs less frequently.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with mitomycin should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.', '3', '"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8703, 0, 'Mitomycin', 'Kidney Diseases', 'Elevations in BUN and/or serum creatinine have been reported during mitomycin therapy.  Therapy with mitomycin should not be administered to patients with serum creatinine > 1.7 mg/dl.  Hemolytic Uremic Syndrome (HUS) has been reported during mitomycin therapy. The incidence of HUS appears to be increased in patients receiving total doses of mitomycin > 60 mg.  Blood product transfusion may exacerbate the symptoms of HUS.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8704, 21947, 'Miglitol', 'Diabetic Ketoacidosis', 'The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.', '3', '"Product Information. Precose (acarbose)." Bayer  (2001):|"Product Information. Glyset (miglitol)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8705, 21948, 'Miglitol', 'Diabetic Ketoacidosis', 'The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.', '3', '"Product Information. Precose (acarbose)." Bayer  (2001):|"Product Information. Glyset (miglitol)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8706, 21947, 'Miglitol', 'Intestinal Diseases', 'The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption.  Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates.  Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.', '3', 'Hollander P "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs 44 Suppl 3 (1992):  47-53|Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988):  214-43|"Product Information. Precose (acarbose)." Bayer  (2001):|Nishii Y, Aizawa T, Hashizume K "Ileus: a rare side effect of acarbose." Diabetes Care 19 (1996):  1033|"Product Information. Glyset (miglitol)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8707, 21948, 'Miglitol', 'Intestinal Diseases', 'The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption.  Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates.  Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.', '3', 'Hollander P "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs 44 Suppl 3 (1992):  47-53|Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988):  214-43|"Product Information. Precose (acarbose)." Bayer  (2001):|Nishii Y, Aizawa T, Hashizume K "Ileus: a rare side effect of acarbose." Diabetes Care 19 (1996):  1033|"Product Information. Glyset (miglitol)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8708, 21947, 'Miglitol', 'Kidney Diseases', 'Miglitol is eliminated primarily by the kidney.  Plasma miglitol levels in patients with renal impairment have been shown to proportionally increase relative to the degree of renal dysfunction.  However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted.  Therapy with miglitol should be administered cautiously in patients with renal insufficiency.  The manufacturer does not recommend its use in patients with significantly impaired renal function.', '3', '"Product Information. Glyset (miglitol)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8709, 21948, 'Miglitol', 'Kidney Diseases', 'Miglitol is eliminated primarily by the kidney.  Plasma miglitol levels in patients with renal impairment have been shown to proportionally increase relative to the degree of renal dysfunction.  However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted.  Therapy with miglitol should be administered cautiously in patients with renal insufficiency.  The manufacturer does not recommend its use in patients with significantly impaired renal function.', '3', '"Product Information. Glyset (miglitol)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8710, 0, 'Migalastat', 'Kidney Diseases', 'Migalastat is substantially excreted by the kidneys.  No dosage adjustment is required in patients with mild to moderate renal impairment (eGFR at least 30 mL/min/1.73 m2 and above).  Migalastat is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.  Systemic exposure was significantly increased in subjects with severe renal impairment (eGFR less than 30 mL/min/1.73 m2).  Migalastat has not been studied in patients with Fabry disease who have an eGFR less than 30 mL/min/1.73 m2.  Care is recommended when using this agent in patients with renal impairment.', '2', '"Product Information. Galafold (migalastat)." Amicus Therapeutics U.S., Inc.  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8711, 0, 'Miltefosine', 'Sjogren-Larsson Syndrome', 'The use of miltefosine is contraindicated in patients with Sjogren-Larsson syndrome.  Miltefosine undergoes metabolic cleavage in hepatocytes to release choline.  The fatty alcohol-containing fragment of miltefosine is then oxidized to palmitic acid, which enters the metabolism of fatty acids.  However, this oxidation is blocked in patients with Sjogren-Larsson syndrome, who have a genetic defect in fatty aldehyde dehydrogenase activity.', '3', '"Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8712, 0, 'Miltefosine', 'Liver Diseases', 'Elevations in liver transaminases (ALT, AST) and bilirubin were observed in clinical trials of miltefosine for the treatment of visceral leishmaniasis.  Patients with serum ALT or AST levels at least 3 times the upper limit of normal and bilirubin levels at least 2 times the upper limit of normal were excluded from clinical trials.  The pharmacokinetics of miltefosine have not been studied in patients with liver dysfunction; caution is recommended.  Liver transaminases (ALT, AST) and bilirubin should be monitored during therapy.', '2', '"Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8713, 0, 'Miltefosine', 'Kidney Diseases', 'Elevations in serum creatinine were observed in clinical trials of miltefosine for the treatment of cutaneous, mucosal, and visceral leishmaniasis.  Patients with serum creatinine or BUN levels at least 1.5 times the upper limit of normal were excluded from clinical trials.  The pharmacokinetics of miltefosine have not been studied in patients with renal dysfunction; caution is recommended.  Renal function should be monitored weekly during therapy and for 4 weeks after completion of therapy.  Abdominal pain, nausea, vomiting, and diarrhea are common side effects of miltefosine; patients should be advised to drink plenty of fluids to avoid dehydration (and, thus, the risk of kidney injury) and to seek medical attention if these gastrointestinal side effects are persistent or severe.', '2', '"Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8714, 0, 'Miltefosine', 'Thrombocytopenia', 'Thrombocytopenia has been reported during treatment of visceral leishmaniasis, including with miltefosine.  Therapy with miltefosine should be administered cautiously in patients with preexisting thrombocytopenia.  Platelet counts should be monitored during therapy for visceral leishmaniasis.', '2', '"Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8715, 229, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8716, 5890, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8717, 7509, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8718, 8215, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8719, 11343, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8720, 13593, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8721, 15379, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8722, 15412, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8723, 19585, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8724, 20186, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8725, 20187, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8726, 20196, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8727, 20197, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8728, 20210, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8729, 20216, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8730, 22799, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8731, 22801, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8732, 22802, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8733, 22803, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8734, 23414, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8735, 24398, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8736, 24743, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8737, 24745, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8738, 25791, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8739, 25792, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8740, 25811, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8741, 25812, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8742, 26586, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8743, 33210, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988):  481-5|Woodside J Jr, Garner L, Beford RF, et al. "Captopril reduces the dose requirement for sodium nitroprusside induced hypotension." Anesthesiology 60 (1984):  413-7|Whitmore SE, Wigley FM, Wise RA "Acute effect of topical minoxidil on digital blood flow in patients with raynaud''s phenomenon." J Rheumatol 22 (1995):  50-4|"PDR Generics." Montvale, NJ: Medical Economics  (1995):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8744, 6693, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8745, 14737, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8746, 22757, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8747, 22758, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8748, 22759, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8749, 22760, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8750, 22761, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8751, 22762, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8752, 23184, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8753, 6693, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8754, 14737, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8755, 22757, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8756, 22758, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8757, 22759, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8758, 22760, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8759, 22761, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8760, 22762, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8761, 23184, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8762, 6693, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8763, 14737, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8764, 22757, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8765, 22758, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8766, 22759, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8767, 22760, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8768, 22761, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8769, 22762, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8770, 23184, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8771, 6693, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8772, 14737, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8773, 22757, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8774, 22758, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8775, 22759, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8776, 22760, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8777, 22761, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8778, 22762, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8779, 23184, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8780, 6693, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8781, 14737, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8782, 22757, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8783, 22758, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8784, 22759, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8785, 22760, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8786, 22761, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8787, 22762, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8788, 23184, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8789, 6693, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8790, 14737, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8791, 22757, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8792, 22758, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8793, 22759, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8794, 22760, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8795, 22761, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8796, 22762, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8797, 23184, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8798, 6693, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8799, 14737, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8800, 22757, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8801, 22758, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8802, 22759, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8803, 22760, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8804, 22761, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8805, 22762, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8806, 23184, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8807, 6693, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8808, 14737, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8809, 22757, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8810, 22758, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8811, 22759, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8812, 22760, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8813, 22761, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8814, 22762, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8815, 23184, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8816, 6693, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8817, 14737, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8818, 22757, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8819, 22758, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8820, 22759, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8821, 22760, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8822, 22761, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8823, 22762, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8824, 23184, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8825, 0, 'Minocycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8826, 0, 'Minocycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8827, 0, 'Minocycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8828, 0, 'Minocycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8829, 0, 'Mitotane', 'Adrenal Insufficiency', 'Mitotane inhibits production of corticosteroids and alters extra-adrenal metabolism of endogenous and exogenous steroids.  All patients treated with mitotane should be instructed to immediately report signs and symptoms of infection or other illnesses.  Therapy with mitotane should be withheld immediately following shock or severe trauma or infection.  Exogenous steroids should be administered since the suppressed adrenal may not immediately begin to secrete steroids.', '3', 'Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR, Stiel JN "The effect of o,p''-DDD on adrenal steroid replacement therapy requirements." Clin Endocrinol (Oxf) 27 (1987):  437-44|"Product Information. Lysodren (mitotane)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8830, 0, 'Mitotane', 'Depressive Disorder', 'Symptoms of depression consisting of lethargy and somnolence have been reported during mitotane therapy.  Therapy with mitotane should be administered cautiously to patients with or predisposed to depression.  Clinical monitoring of psychological behavior is recommended.', '2', '"Product Information. Lysodren (mitotane)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8831, 0, 'Mitotane', 'Liver Diseases', 'Mitotane is primarily metabolized by the liver.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Therapy with mitotane should be administered cautiously in patients with hepatic impairment.  Clinical monitoring of hepatic function is recommended.', '2', '"Product Information. Lysodren (mitotane)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8832, 0, 'Mitotane', 'Nervous System Diseases', 'Unspecified brain damage and impairment of function have been reported during prolonged mitotane therapy.  Therapy with mitotane should be administered cautiously to patients with neurologic impairment.  Clinical monitoring of behavior and neurological function is recommended when continuous mitotane therapy exceeds two years.', '2', 'Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC "o,p''-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement." Cancer 42 (1978):  2177-81|Lanser JB, van Seters AP, Moolenaar AJ, Haak HR, Bollen EL "Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms." J Clin Oncol 10 (1992):  1504|"Product Information. Lysodren (mitotane)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8833, 0, 'Mitotane', 'Perimenopause', 'Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving mitotane which might lead to adnexal torsion and hemorrhagic cyst rupture.  It is recommended to use care when using this agent in premenopausal patients and to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain.', '2', '"Product Information. Lysodren (mitotane)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8834, 0, 'Mogamulizumab', 'Autoimmune Diseases', 'Fatal and life-threatening immune-mediated complications have been reported in recipients of mogamulizumab.  Grade 3 or higher immune-mediated or possibly immune-mediated reactions have included myositis, myocarditis, polymyositis, hepatitis, pneumonitis, and a variant of Guillain- Barr syndrome.  Interrupt or permanently discontinue therapy as appropriate for suspected immune-mediated adverse reactions.  Consider the benefit/risk of using mogamulizumab in patients with a history of autoimmune disease.', '2', '"Product Information. Poteligeo (mogamulizumab)." Kyowa Kirin, Inc  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8835, 0, 'Mivacurium', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8836, 0, 'Mivacurium', 'Burns', 'Patients with burns may develop resistance to non-depolarizing neuromuscular blocking agents.  These patients may experience a shorter duration of action and/or require higher dosages of the drugs.  The extent of altered response depends on the duration since and the size of the burn.', '3', '"Product Information. Zemuron (rocuronium)." Organon  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8837, 0, 'Mivacurium', 'Hypersensitivity', 'Some neuromuscular blocking agents stimulate the release of histamine, which can cause wheezing, bronchospasm, increased bronchial secretions, hypotension, tachycardia, and circulatory collapse.  Hypotension may also occur due to ganglionic blockade or as a complication of positive pressure respiration.  Tubocurarine appears to be the most potent inducer of histamine, followed by metocurine (no longer commercially available in the U.S.) and succinylcholine.  Other agents with varying but lesser degrees of histamine-releasing properties include atracurium, mivacurium, and pancuronium (at excessive dosages).  Therapy with these neuromuscular blocking agents should be administered cautiously in patients with clinically significant cardiovascular disease and/or a history of asthma or severe allergic reactions.  Certain agents may prolong the QTc interval, especially during general anesthesia in pediatric patients.  The initial dosage and rate of administration may need to be reduced, and hemodynamic and respiratory status carefully monitored.  Neuromuscular blocking agents that appear to have little or no histamine-inducing effects include cisatracurium, doxacurium, pipecuronium, rocuronium, and vecuronium.', '3', '"Product Information. Zemuron (rocuronium)." Organon  (2001):|"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|"Product Information. Norcuron (vecuronium)." Organon  (2001):|"Product Information. Metubine Iodide (metocurine)." Dista Products Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8838, 0, 'Mivacurium', 'Liver Diseases', 'Neuromuscular blocking agents undergo metabolism by the liver.  Elimination and effects may be prolonged in patients with liver disease.  Therapy with neuromuscular blocking agents should be administered cautiously in patients with liver disease.', '3', '"Product Information. Zemuron (rocuronium)." Organon  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Norcuron (vecuronium)." Organon  (2001):|"Product Information. Metubine Iodide (metocurine)." Dista Products Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8839, 0, 'Mivacurium', 'Myasthenia Gravis', 'The use of neuromuscular blocking agents may cause prolonged respiratory paralysis.  Therapy with neuromuscular blocking agents should be administered cautiously in patients with myasthenia gravis.  Use of a peripheral nerve stimulator may be helpful in evaluating the level of neuromuscular blockade.', '3', '"Product Information. Zemuron (rocuronium)." Organon  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|"Product Information. Metubine Iodide (metocurine)." Dista Products Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8840, 0, 'Mivacurium', 'Paresis', 'Patients with hemiparesis or paraparesis may require higher dosages of non-depolarizing neuromuscular blocking agents in the affected limbs.  Neuromuscular monitoring should be performed on a non-paretic limb to avoid inaccurate dosing.', '3', '"Product Information. Zemuron (rocuronium)." Organon  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|"Product Information. Norcuron (vecuronium)." Organon  (2001):|"Product Information. Metubine Iodide (metocurine)." Dista Products Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8841, 0, 'Mivacurium', 'Respiratory Insufficiency', 'Neuromuscular blocking agents can cause respiratory depression and paralysis.  Therapy with neuromuscular blocking agents should be administered cautiously in patients with pulmonary impairment.  Treatment of respiratory paralysis consists of positive-pressure artificial respiration with oxygen and maintenance of a patent airway until the recovery of normal respiration is assured.', '3', '"Product Information. Zemuron (rocuronium)." Organon  (2001):|"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|"Product Information. Norcuron (vecuronium)." Organon  (2001):|"Product Information. Metubine Iodide (metocurine)." Dista Products Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8842, 0, 'Mivacurium', 'Obesity', 'A few of the neuromuscular blocking agents, including doxacurium, mivacurium and pipecuronium, may have prolonged and/or enhanced effects in obese patients (i.e. weight >= 30% over ideal body weight for height).  Dosing of these agents should be based on ideal body weight in obese patients.', '2', '"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8843, 0, 'Mivacurium', 'Kidney Diseases', 'Many of the non-depolarizing (competitive) neuromuscular blocking agents undergo significant elimination by the kidney.  Their effects may, therefore, be prolonged in patients with renal dysfunction.  Therapy with these neuromuscular blocking agents should be administered cautiously and initiated at reduced dosages in renally compromised patients, depending on the level of insufficiency.  If possible, alternative agents should be considered.  Atracurium, rocuronium and vecuronium do not depend on kidney function for clearance and are often the non-depolarizing muscle relaxants of choice in renal failure.', '2', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Zemuron (rocuronium)." Organon  (2001):|"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|"Product Information. Norcuron (vecuronium)." Organon  (2001):|"Product Information. Metubine Iodide (metocurine)." Dista Products Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8844, 202, 'Ascorbic acid', 'Hemolysis', 'Acute hemolysis following administration of high doses of ascorbic acid in patients with glucose-6-phosphate deficiency (G6PD) has been reported.  Ascorbic acid should be administered cautiously and dosages modified in patients with G6PD.', '2', '"Product Information. Cemill 500 (ascorbic acid)." Abbott Pharmaceutical', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8845, 202, 'Ascorbic acid', 'Kidney Calculi', 'Large doses of ascorbic acid have lead to hyperoxaluria in 5% of patients.  Ascorbic acid can acidify urine resulting in precipitation of urate, cystine, or oxalate stones.  Ascorbic acid should be administered cautiously and dosages modified in patients predisposed to renal stones.  Clinical monitoring of urinalysis for pH and crystal formation is recommended.', '2', '"Product Information. Cemill 500 (ascorbic acid)." Abbott Pharmaceutical', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8846, 202, 'Ascorbic acid', 'Heart Failure', 'Ascorbic acid preparations contain sodium.  The sodium content should be considered when used in patients with sodium restricted diets and conditions require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cemill 500 (ascorbic acid)." Abbott Pharmaceutical', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8847, 202, 'Ascorbic acid', 'Diseases requiring dialysis', 'Ascorbic acid is removed by dialysis.', '1', '"Product Information. Cemill 500 (ascorbic acid)." Abbott Pharmaceutical', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8848, 0, 'Molindone', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8849, 0, 'Molindone', 'Central Nervous System Diseases', 'The use of most miscellaneous antipsychotics is contraindicated in patients with severe central nervous system depression or comatose states from any cause (e.g., lesion, disease, drug or alcohol induced).', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Adasuve (loxapine)." Teva Pharmaceuticals USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8850, 0, 'Molindone', 'Neuroleptic Malignant Syndrome', 'Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with the use of antipsychotic drugs.  The diagnostic evaluation is complicated and the management requires immediate discontinuation of the antipsychotic therapy and intensive symptomatic treatment and medical monitoring.  If a patient that has recovered from NMS requires antipsychotic drug treatment again, the reintroduction of therapy should be carefully considered as NMS recurrences have been reported.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Eskalith (lithium)." SmithKline Beecham  (2002):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Adasuve (loxapine)." Teva Pharmaceuticals USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8851, 0, 'Molindone', 'Epilepsy', 'Antipsychotics can lower the seizure threshold and trigger seizures in a dose-dependent manner.  Seizures have been reported in patients receiving antipsychotic therapy and may occur in epileptic patients even with maintenance of routine anticonvulsant treatment.  Therapy with antipsychotics should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  High dosages should be avoided if possible.', '3', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Lowry MR, Dunner FJ "Seizures during tricyclic therapy." Am J Psychiatry 137 (1980):  1461-2|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Eskalith (lithium)." SmithKline Beecham  (2002):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8852, 0, 'Molindone', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8853, 0, 'Molindone', 'Cardiovascular Diseases', 'Neuroleptic agents may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include hypertension, edema, arrhythmias, thrombophlebitis, myocarditis, angina, myocardial infarction, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with neuroleptic agents should be administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since neuroleptic agents can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Huyse F, van Schijndel RS "Haloperidol and cardiac arrest." Lancet 2 (1988):  568-9|McCance-Katz EF "New onset Raynaud''s phenomenon in a schizophrenic patient ." J Clin Psychiatry 52 (1991):  89-90|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Lieberman JA, Safferman AZ "Clinical profile of clozapine: adverse reactions and agranulocytosis." Psychiatr Q 63 (1992):  51-70|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Wilt JL, Minnema AM, Johnson RF, Rosenblum AM "Torsade de pointes associated with the use of intravenous haloperidol." Ann Intern Med 119 (1993):  391-4|Metzger E, Friedman R "Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill." J Clin Psychopharmacol 13 (1993):  128-32|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Kerwin R "Adverse reaction reporting and new antipsychotics." Lancet 342 (1993):  1440|Gupta S "Paradoxical hypertension associated with clozapine." Am J Psychiatry 151 (1994):  148|Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG "Clozapine and metabolites - concentrations in serum and clinical findings during treatment of chronically psychotic patients." J Clin Psychopharmacol 14 (1994):  119-25|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Testani M "Clozapine-induced orthostatic hypotension treated with fludrocortisone." J Clin Psychiatry 55 (1994):  497-8|Aronowitz JS, Umbricht DSG, Safferman AZ "Clozapine and new-onset ECG abnormalities." Psychosomatics 36 (1995):  82-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Baldassano CF, Ghaemi SN "Generalized edema with risperidone: divalproex sodium treatment." J Clin Psychiatry 57 (1996):  422|Ravin DS, Levenson JW "Fatal cardiac event following initiation of risperidone therapy." Ann Pharmacother 31 (1997):  867-70|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|O''Brien JM, Rockwood RP, Suh KI "Haloperidol-induced torsade de pointes." Ann Pharmacother 33 (1999):  1046-9|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezawa Y "The association between intravenous haloperidol and prolonged QT interval." J Clin Psychopharmacol 21 (2001):  257-61|La Grenade L, Graham D, Trontell A "Myocarditis and cardiomyopathy associated with clozapine use in the United States." N Engl J Med 345 (2001):  224-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8854, 0, 'Molindone', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8855, 0, 'Molindone', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8856, 0, 'Molindone', 'Hyperprolactinemia', 'Antipsychotic drugs can elevate serum prolactin concentrations, and this elevation persists during chronic administration.  This should be considered if therapy will be prescribed in patients with previously detected breast cancer as one-third of human breast cancers are prolactin-dependent in vitro.  Associated disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported.  Appropriate laboratory testing and follow-up is advised.', '2', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Eskalith (lithium)." SmithKline Beecham  (2002):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Adasuve (loxapine)." Teva Pharmaceuticals USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8857, 0, 'Molindone', 'Intestinal Obstruction', 'Some antipsychotics such as loxapine and molindone have antiemetic effects and may mask signs of overdosage of toxic drugs, and may obscure conditions such as intestinal obstruction and brain tumor.', '2', '"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Adasuve (loxapine)." Teva Pharmaceuticals USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8858, 0, 'Molindone', 'Neutropenia', 'The use of antipsychotics has been associated with events of leukopenia, neutropenia and agranulocytosis.  Possible risk factors include preexisting low white blood cell count, and history of drug induced leukopenia/neutropenia.  Patients with these risk factors should have complete blood count monitored frequently during the first few months of therapy.  Patients should also be monitored for any signs or symptoms of infection.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count or severe neutropenia (ANC < 1000/mm3).', '2', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Eskalith (lithium)." SmithKline Beecham  (2002):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Adasuve (loxapine)." Teva Pharmaceuticals USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8859, 0, 'Molindone', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8860, 0, 'Molindone', 'Dehydration', 'Neuroleptic agents may cause hypotension (including orthostatic hypotension) and associated reflex tachycardia, syncope or dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Tolerance to the hypotensive effects often develops after a few doses to a few months.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Therapy with neuroleptic agents should be administered cautiously in patients with conditions that would predispose them to hypotension, such as hypovolemia or dehydration (e.g., due to severe diarrhea or vomiting).  In addition, neuroleptic agents can interfere with the body''s ability to regulate core body temperature, occasionally producing hyperthermia during strenuous exercise, exposure to hot weather, and concomitant treatment with anticholinergic medications.  Patients who are dehydrated may be particularly susceptible.', '2', '"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8861, 0, 'Molindone', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8862, 0, 'Molindone', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8863, 0, 'Molindone', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8864, 8243, 'Mitoxantrone', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8865, 24127, 'Mitoxantrone', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8866, 26545, 'Mitoxantrone', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8867, 8243, 'Mitoxantrone', 'Heart Diseases', 'Mitoxantrone can cause myocardial toxicity leading to congestive heart failure (CHF).  Patients with preexisting heart disease, prior irradiation, previous therapy with related compounds such as daunorubicin, idarubicin or doxorubicin, or of advanced age are at increased risk of cardiotoxicity at a lower cumulative dose.  The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of mitoxantrone exceeds 140 mg/m2.  Close clinical monitoring of cardiac function, such as determination of left ventricular ejection fraction, prior to each course of therapy is recommended.', '3', 'Janmohammed R, Milligan DW "Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines." Br J Haematol 71 (1989):  292-3|Pai GR, Reed NS, Ruddell WS "A case of mitozantrone-associated cardiomyopathy without prior anthracycline therapy." Br J Radiol 60 (1987):  1125-6|Fountzilas G, Afthonidis D, Geleris P, Salem N, Kottas G, Halkidis C, Apostolidis P, Beer M, Tourkantonis A "Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer." Anticancer Res 12 (1992):  231-4|Schell FC, Yap HY, Blumenschein G, Valdivieso M, Bodey G "Potential cardiotoxicity with mitoxantrone." Cancer Treat Rep 66 (1982):  1641-3|Mather FJ, Simon RM, Clark GM, Von Hoff DD "Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies." Cancer Treat Rep 71 (1987):  609-13|de Leonardis V, Bartalucci S, Cinelli P, De Scalzi M, Becucci A, Lottini G, Neri B "Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity." Cardiology 79 (1991):  110-5|Villani F, Galimberti M, Crippa F "Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone." Drugs Exp Clin Res 15 (1989):  501-6|Cassidy J, Merrick MV, Smyth JF, Leonard RC "Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography." Eur J Cancer Clin Oncol 24 (1988):  935-8|Lewkow LM, Hooker JL, Movahed A "Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer." Int J Cardiol 34 (1992):  273-6|Benjamin RS "Rationale for the use of mitoxantrone in the older patient: cardiac toxicity." Semin Oncol 22 (1 Suppl) (1995):  11-3|LeMaistre CF, Herzig R "Mitoxantrone: potential for use in intensive therapy." Semin Oncol 17 (1 Suppl) (1990):  43-8|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|Benekli M, Kars A, Guler N "Mitoxamtrone-induced bradycardia." Ann Intern Med 126 (1997):  409', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8868, 24127, 'Mitoxantrone', 'Heart Diseases', 'Mitoxantrone can cause myocardial toxicity leading to congestive heart failure (CHF).  Patients with preexisting heart disease, prior irradiation, previous therapy with related compounds such as daunorubicin, idarubicin or doxorubicin, or of advanced age are at increased risk of cardiotoxicity at a lower cumulative dose.  The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of mitoxantrone exceeds 140 mg/m2.  Close clinical monitoring of cardiac function, such as determination of left ventricular ejection fraction, prior to each course of therapy is recommended.', '3', 'Janmohammed R, Milligan DW "Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines." Br J Haematol 71 (1989):  292-3|Pai GR, Reed NS, Ruddell WS "A case of mitozantrone-associated cardiomyopathy without prior anthracycline therapy." Br J Radiol 60 (1987):  1125-6|Fountzilas G, Afthonidis D, Geleris P, Salem N, Kottas G, Halkidis C, Apostolidis P, Beer M, Tourkantonis A "Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer." Anticancer Res 12 (1992):  231-4|Schell FC, Yap HY, Blumenschein G, Valdivieso M, Bodey G "Potential cardiotoxicity with mitoxantrone." Cancer Treat Rep 66 (1982):  1641-3|Mather FJ, Simon RM, Clark GM, Von Hoff DD "Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies." Cancer Treat Rep 71 (1987):  609-13|de Leonardis V, Bartalucci S, Cinelli P, De Scalzi M, Becucci A, Lottini G, Neri B "Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity." Cardiology 79 (1991):  110-5|Villani F, Galimberti M, Crippa F "Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone." Drugs Exp Clin Res 15 (1989):  501-6|Cassidy J, Merrick MV, Smyth JF, Leonard RC "Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography." Eur J Cancer Clin Oncol 24 (1988):  935-8|Lewkow LM, Hooker JL, Movahed A "Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer." Int J Cardiol 34 (1992):  273-6|Benjamin RS "Rationale for the use of mitoxantrone in the older patient: cardiac toxicity." Semin Oncol 22 (1 Suppl) (1995):  11-3|LeMaistre CF, Herzig R "Mitoxantrone: potential for use in intensive therapy." Semin Oncol 17 (1 Suppl) (1990):  43-8|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|Benekli M, Kars A, Guler N "Mitoxamtrone-induced bradycardia." Ann Intern Med 126 (1997):  409', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8869, 26545, 'Mitoxantrone', 'Heart Diseases', 'Mitoxantrone can cause myocardial toxicity leading to congestive heart failure (CHF).  Patients with preexisting heart disease, prior irradiation, previous therapy with related compounds such as daunorubicin, idarubicin or doxorubicin, or of advanced age are at increased risk of cardiotoxicity at a lower cumulative dose.  The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of mitoxantrone exceeds 140 mg/m2.  Close clinical monitoring of cardiac function, such as determination of left ventricular ejection fraction, prior to each course of therapy is recommended.', '3', 'Janmohammed R, Milligan DW "Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines." Br J Haematol 71 (1989):  292-3|Pai GR, Reed NS, Ruddell WS "A case of mitozantrone-associated cardiomyopathy without prior anthracycline therapy." Br J Radiol 60 (1987):  1125-6|Fountzilas G, Afthonidis D, Geleris P, Salem N, Kottas G, Halkidis C, Apostolidis P, Beer M, Tourkantonis A "Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer." Anticancer Res 12 (1992):  231-4|Schell FC, Yap HY, Blumenschein G, Valdivieso M, Bodey G "Potential cardiotoxicity with mitoxantrone." Cancer Treat Rep 66 (1982):  1641-3|Mather FJ, Simon RM, Clark GM, Von Hoff DD "Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies." Cancer Treat Rep 71 (1987):  609-13|de Leonardis V, Bartalucci S, Cinelli P, De Scalzi M, Becucci A, Lottini G, Neri B "Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity." Cardiology 79 (1991):  110-5|Villani F, Galimberti M, Crippa F "Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone." Drugs Exp Clin Res 15 (1989):  501-6|Cassidy J, Merrick MV, Smyth JF, Leonard RC "Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography." Eur J Cancer Clin Oncol 24 (1988):  935-8|Lewkow LM, Hooker JL, Movahed A "Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer." Int J Cardiol 34 (1992):  273-6|Benjamin RS "Rationale for the use of mitoxantrone in the older patient: cardiac toxicity." Semin Oncol 22 (1 Suppl) (1995):  11-3|LeMaistre CF, Herzig R "Mitoxantrone: potential for use in intensive therapy." Semin Oncol 17 (1 Suppl) (1990):  43-8|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|Benekli M, Kars A, Guler N "Mitoxamtrone-induced bradycardia." Ann Intern Med 126 (1997):  409', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8870, 8243, 'Mitoxantrone', 'Liver Diseases', 'Hepatic impairment reduces mitoxantrone clearance.  Patients with severe hepatic dysfunction (bilirubin > 3.4 mg/dL) have an AUC more than three times greater than that of patients with normal hepatic function receiving the same dose.  Therapy with mitoxantrone should be administered cautiously to patients with significantly compromised hepatic function.', '3', 'Paciucci PA, Sklarin NT "Mitoxantrone and hepatic toxicity." Ann Intern Med 105 (1986):  805-6|Keller JW, Omura GA, Gams RA, Bartolucci AA "Weekly mitoxantrone therapy of Hodgkin''s disease, non-Hodgkin''s lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial." Am J Clin Oncol 10 (1987):  194-5|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8871, 24127, 'Mitoxantrone', 'Liver Diseases', 'Hepatic impairment reduces mitoxantrone clearance.  Patients with severe hepatic dysfunction (bilirubin > 3.4 mg/dL) have an AUC more than three times greater than that of patients with normal hepatic function receiving the same dose.  Therapy with mitoxantrone should be administered cautiously to patients with significantly compromised hepatic function.', '3', 'Paciucci PA, Sklarin NT "Mitoxantrone and hepatic toxicity." Ann Intern Med 105 (1986):  805-6|Keller JW, Omura GA, Gams RA, Bartolucci AA "Weekly mitoxantrone therapy of Hodgkin''s disease, non-Hodgkin''s lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial." Am J Clin Oncol 10 (1987):  194-5|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8872, 26545, 'Mitoxantrone', 'Liver Diseases', 'Hepatic impairment reduces mitoxantrone clearance.  Patients with severe hepatic dysfunction (bilirubin > 3.4 mg/dL) have an AUC more than three times greater than that of patients with normal hepatic function receiving the same dose.  Therapy with mitoxantrone should be administered cautiously to patients with significantly compromised hepatic function.', '3', 'Paciucci PA, Sklarin NT "Mitoxantrone and hepatic toxicity." Ann Intern Med 105 (1986):  805-6|Keller JW, Omura GA, Gams RA, Bartolucci AA "Weekly mitoxantrone therapy of Hodgkin''s disease, non-Hodgkin''s lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial." Am J Clin Oncol 10 (1987):  194-5|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8873, 8243, 'Mitoxantrone', 'Bone Marrow Failure Disorders', 'Mitoxantrone induces myelosuppression when administered at therapeutic doses indicated for treatment of leukemia.  Leukopenia is the most profound hematologic side-effect.  Thrombocytopenia is rare, but can be severe and erythrocytes do not appear to be significantly affected.  Therapy with mitoxantrone should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering mitoxantrone.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', 'Faulds D, Balfour JA, Chrisp P, Langtry HD "Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer." Drugs 41 (1991):  400-49|Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA "A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia." J Clin Oncol 5 (1987):  391-7|Neijt JP, Lacave AJ, Splinter TA, Taal BG, Veenhof CH, Sahmoud T, Lips CJ "Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group." Br J Cancer 71 (1995):  106-8|Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D "Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer." J Clin Oncol 7 (1989):  560-71|Dugan M, Choy D, Ngai A, Sham J, Choi P, Shiu W, Leung T, Teo P, Prasad U, Lee S, et al. "Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study." J Clin Oncol 11 (1993):  70-6|Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Hoskins W "Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer." J Clin Oncol 9 (1991):  978-82|Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RG "Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer." Lancet 335 (1990):  186-90|Powles TI, Ashley S "Myelosuppression after methotrexate, mitozantrone, and mitomycin C combination chemotherapy." Lancet 2 (1987):  853|Jodrell DI, Iveson TJ, Smith IE "Myelosuppression after methotrexate, mitoxantrone, and mitomycin C." Lancet 1 (1987):  1211|Morton AR, Anderson H, Howell A "Myelotoxicity of methotrexate, mitozantrone, and mitomycin C." Lancet 1 (1987):  1494|Bajetta E, Buzzoni R, Valagussa P, Bonadonna G "Mitoxantrone: an active agent in refractory non-Hodgkin''s lymphomas." Am J Clin Oncol 11 (1988):  100-3|Keller JW, Omura GA, Gams RA, Bartolucci AA "Weekly mitoxantrone therapy of Hodgkin''s disease, non-Hodgkin''s lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial." Am J Clin Oncol 10 (1987):  194-5|Saletan S "Mitoxantrone: an active, new antitumor agent with an improved therapeutic index." Cancer Treat Rev 14 (1987):  297-303|Muhonen TT, Wiklund TA, Blomqvist CP, Pyrhonen SO "Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate." Eur J Cancer 28a (1992):  1974-6|LeMaistre CF, Herzig R "Mitoxantrone: potential for use in intensive therapy." Semin Oncol 17 (1 Suppl) (1990):  43-8|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8874, 24127, 'Mitoxantrone', 'Bone Marrow Failure Disorders', 'Mitoxantrone induces myelosuppression when administered at therapeutic doses indicated for treatment of leukemia.  Leukopenia is the most profound hematologic side-effect.  Thrombocytopenia is rare, but can be severe and erythrocytes do not appear to be significantly affected.  Therapy with mitoxantrone should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering mitoxantrone.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', 'Faulds D, Balfour JA, Chrisp P, Langtry HD "Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer." Drugs 41 (1991):  400-49|Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA "A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia." J Clin Oncol 5 (1987):  391-7|Neijt JP, Lacave AJ, Splinter TA, Taal BG, Veenhof CH, Sahmoud T, Lips CJ "Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group." Br J Cancer 71 (1995):  106-8|Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D "Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer." J Clin Oncol 7 (1989):  560-71|Dugan M, Choy D, Ngai A, Sham J, Choi P, Shiu W, Leung T, Teo P, Prasad U, Lee S, et al. "Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study." J Clin Oncol 11 (1993):  70-6|Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Hoskins W "Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer." J Clin Oncol 9 (1991):  978-82|Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RG "Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer." Lancet 335 (1990):  186-90|Powles TI, Ashley S "Myelosuppression after methotrexate, mitozantrone, and mitomycin C combination chemotherapy." Lancet 2 (1987):  853|Jodrell DI, Iveson TJ, Smith IE "Myelosuppression after methotrexate, mitoxantrone, and mitomycin C." Lancet 1 (1987):  1211|Morton AR, Anderson H, Howell A "Myelotoxicity of methotrexate, mitozantrone, and mitomycin C." Lancet 1 (1987):  1494|Bajetta E, Buzzoni R, Valagussa P, Bonadonna G "Mitoxantrone: an active agent in refractory non-Hodgkin''s lymphomas." Am J Clin Oncol 11 (1988):  100-3|Keller JW, Omura GA, Gams RA, Bartolucci AA "Weekly mitoxantrone therapy of Hodgkin''s disease, non-Hodgkin''s lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial." Am J Clin Oncol 10 (1987):  194-5|Saletan S "Mitoxantrone: an active, new antitumor agent with an improved therapeutic index." Cancer Treat Rev 14 (1987):  297-303|Muhonen TT, Wiklund TA, Blomqvist CP, Pyrhonen SO "Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate." Eur J Cancer 28a (1992):  1974-6|LeMaistre CF, Herzig R "Mitoxantrone: potential for use in intensive therapy." Semin Oncol 17 (1 Suppl) (1990):  43-8|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8875, 26545, 'Mitoxantrone', 'Bone Marrow Failure Disorders', 'Mitoxantrone induces myelosuppression when administered at therapeutic doses indicated for treatment of leukemia.  Leukopenia is the most profound hematologic side-effect.  Thrombocytopenia is rare, but can be severe and erythrocytes do not appear to be significantly affected.  Therapy with mitoxantrone should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering mitoxantrone.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', 'Faulds D, Balfour JA, Chrisp P, Langtry HD "Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer." Drugs 41 (1991):  400-49|Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA "A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia." J Clin Oncol 5 (1987):  391-7|Neijt JP, Lacave AJ, Splinter TA, Taal BG, Veenhof CH, Sahmoud T, Lips CJ "Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group." Br J Cancer 71 (1995):  106-8|Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D "Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer." J Clin Oncol 7 (1989):  560-71|Dugan M, Choy D, Ngai A, Sham J, Choi P, Shiu W, Leung T, Teo P, Prasad U, Lee S, et al. "Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study." J Clin Oncol 11 (1993):  70-6|Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Hoskins W "Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer." J Clin Oncol 9 (1991):  978-82|Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RG "Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer." Lancet 335 (1990):  186-90|Powles TI, Ashley S "Myelosuppression after methotrexate, mitozantrone, and mitomycin C combination chemotherapy." Lancet 2 (1987):  853|Jodrell DI, Iveson TJ, Smith IE "Myelosuppression after methotrexate, mitoxantrone, and mitomycin C." Lancet 1 (1987):  1211|Morton AR, Anderson H, Howell A "Myelotoxicity of methotrexate, mitozantrone, and mitomycin C." Lancet 1 (1987):  1494|Bajetta E, Buzzoni R, Valagussa P, Bonadonna G "Mitoxantrone: an active agent in refractory non-Hodgkin''s lymphomas." Am J Clin Oncol 11 (1988):  100-3|Keller JW, Omura GA, Gams RA, Bartolucci AA "Weekly mitoxantrone therapy of Hodgkin''s disease, non-Hodgkin''s lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial." Am J Clin Oncol 10 (1987):  194-5|Saletan S "Mitoxantrone: an active, new antitumor agent with an improved therapeutic index." Cancer Treat Rev 14 (1987):  297-303|Muhonen TT, Wiklund TA, Blomqvist CP, Pyrhonen SO "Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate." Eur J Cancer 28a (1992):  1974-6|LeMaistre CF, Herzig R "Mitoxantrone: potential for use in intensive therapy." Semin Oncol 17 (1 Suppl) (1990):  43-8|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8876, 8243, 'Mitoxantrone', 'Hyperuricemia', 'Treatment with mitoxantrone may cause hyperuricemia as a result of rapid lysis of tumor cells.  Levels of serum uric acid should be monitored and appropriate therapy should be initiated before starting therapy.', '2', '"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8877, 24127, 'Mitoxantrone', 'Hyperuricemia', 'Treatment with mitoxantrone may cause hyperuricemia as a result of rapid lysis of tumor cells.  Levels of serum uric acid should be monitored and appropriate therapy should be initiated before starting therapy.', '2', '"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8878, 26545, 'Mitoxantrone', 'Hyperuricemia', 'Treatment with mitoxantrone may cause hyperuricemia as a result of rapid lysis of tumor cells.  Levels of serum uric acid should be monitored and appropriate therapy should be initiated before starting therapy.', '2', '"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8879, 15465, 'Modafinil', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8880, 22882, 'Modafinil', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8881, 22887, 'Modafinil', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8882, 15465, 'Modafinil', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8883, 22882, 'Modafinil', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8884, 22887, 'Modafinil', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8885, 15465, 'Modafinil', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8886, 22882, 'Modafinil', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8887, 22887, 'Modafinil', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8888, 15465, 'Modafinil', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8889, 22882, 'Modafinil', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8890, 22887, 'Modafinil', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8891, 15465, 'Modafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8892, 22882, 'Modafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8893, 22887, 'Modafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8894, 15465, 'Modafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8895, 22882, 'Modafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8896, 22887, 'Modafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8897, 15465, 'Modafinil', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8898, 22882, 'Modafinil', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8899, 22887, 'Modafinil', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8900, 15465, 'Modafinil', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8901, 22882, 'Modafinil', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8902, 22887, 'Modafinil', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8903, 15465, 'Modafinil', 'Cardiovascular Diseases', 'In clinical trials, a few patients treated with modafinil developed chest pain, palpitations, dyspnea and transient ischemic T-wave changes in association with mitral valve prolapse or left ventricular hypertrophy.  The manufacturer recommends that modafinil not be used in patients with a history of left ventricular hypertrophy or ischemic ECG changes, chest pain, arrhythmia or other clinically significant manifestations of mitral valve prolapse in association with central nervous system (CNS) stimulant use.  In addition, caution is advised in patients with cardiovascular disease due to other causes, particularly hypertension and/or a recent history of myocardial infarction or unstable angina, since the use of modafinil has not been evaluated in such patients.', '2', '"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8904, 22882, 'Modafinil', 'Cardiovascular Diseases', 'In clinical trials, a few patients treated with modafinil developed chest pain, palpitations, dyspnea and transient ischemic T-wave changes in association with mitral valve prolapse or left ventricular hypertrophy.  The manufacturer recommends that modafinil not be used in patients with a history of left ventricular hypertrophy or ischemic ECG changes, chest pain, arrhythmia or other clinically significant manifestations of mitral valve prolapse in association with central nervous system (CNS) stimulant use.  In addition, caution is advised in patients with cardiovascular disease due to other causes, particularly hypertension and/or a recent history of myocardial infarction or unstable angina, since the use of modafinil has not been evaluated in such patients.', '2', '"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8905, 22887, 'Modafinil', 'Cardiovascular Diseases', 'In clinical trials, a few patients treated with modafinil developed chest pain, palpitations, dyspnea and transient ischemic T-wave changes in association with mitral valve prolapse or left ventricular hypertrophy.  The manufacturer recommends that modafinil not be used in patients with a history of left ventricular hypertrophy or ischemic ECG changes, chest pain, arrhythmia or other clinically significant manifestations of mitral valve prolapse in association with central nervous system (CNS) stimulant use.  In addition, caution is advised in patients with cardiovascular disease due to other causes, particularly hypertension and/or a recent history of myocardial infarction or unstable angina, since the use of modafinil has not been evaluated in such patients.', '2', '"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8906, 22796, 'Moexipril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8907, 25252, 'Moexipril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8908, 25253, 'Moexipril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8909, 22796, 'Moexipril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8910, 25252, 'Moexipril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8911, 25253, 'Moexipril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8912, 22796, 'Moexipril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8913, 25252, 'Moexipril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8914, 25253, 'Moexipril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8915, 22796, 'Moexipril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8916, 25252, 'Moexipril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8917, 25253, 'Moexipril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8918, 22796, 'Moexipril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8919, 25252, 'Moexipril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8920, 25253, 'Moexipril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8921, 22796, 'Moexipril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8922, 25252, 'Moexipril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8923, 25253, 'Moexipril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8924, 22796, 'Moexipril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8925, 25252, 'Moexipril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8926, 25253, 'Moexipril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8927, 22796, 'Moexipril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8928, 25252, 'Moexipril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8929, 25253, 'Moexipril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8930, 780, 'Monopotassium phosphate', 'Hypocalcemia', 'The use of phosphates is in general contraindicated in conditions where high potassium, high phosphate, or low calcium may be encountered such as hypoparathyroidism, osteomalacia, acute pancreatitis, or chronic renal disease.', '3', '"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|"Product Information. Fleet Enema (sodium acid phophate-sodium phosphate)." Fleet  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8931, 780, 'Monopotassium phosphate', 'Renal Insufficiency', 'Potassium phosphate injections contains aluminum that may be toxic.  Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impairment.  Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum.  Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day of parenteral aluminum can accumulate aluminum to levels associated with central nervous system and bone toxicity.  Potassium phosphate injection for parenteral nutrition is not recommended in adults weighing less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due to the risks of aluminum toxicity.', '2', '"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8932, 780, 'Monopotassium phosphate', 'Heart Diseases', 'Potassium phosphate injection may increase the risk of hyperkalemia.  Patients with cardiac disease may be more susceptible to the effects of hyperkalemia.  Caution is advised when using potassium phosphates in patients with heart disease.  Continuous electrocardiographic (ECG) monitoring is recommended for higher infusion rates of potassium.', '2', '"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8933, 780, 'Monopotassium phosphate', 'Hypomagnesemia 1, Intestinal', 'Intravenous infusion of phosphate has been reported to cause a decrease in serum magnesium (and calcium) concentrations when administered to patients with hypercalcemia and diabetic ketoacidosis.  Monitor serum magnesium concentrations during treatment.  Caution is advised in patients with magnesium imbalances.', '2', '"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8934, 1008, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8935, 1011, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8936, 2730, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8937, 2731, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8938, 6792, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8939, 6794, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8940, 6987, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8941, 6988, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8942, 7190, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8943, 8315, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8944, 8317, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8945, 10252, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8946, 10253, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8947, 10513, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8948, 10515, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8949, 14467, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8950, 14469, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8951, 16478, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8952, 17208, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8953, 17209, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8954, 20714, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8955, 20715, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8956, 20840, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8957, 20841, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8958, 21685, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8959, 21687, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8960, 22941, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8961, 22942, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8962, 22944, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8963, 22946, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8964, 22947, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8965, 22948, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8966, 22949, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8967, 22950, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8968, 22951, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8969, 22952, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8970, 24144, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8971, 24145, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8972, 24958, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8973, 25842, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8974, 27039, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8975, 27042, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8976, 27043, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8977, 27482, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8978, 27483, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8979, 29649, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8980, 1008, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8981, 1011, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8982, 2730, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8983, 2731, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8984, 6792, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8985, 6794, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8986, 6987, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8987, 6988, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8988, 7190, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8989, 8315, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8990, 8317, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8991, 10252, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8992, 10253, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8993, 10513, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8994, 10515, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8995, 14467, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8996, 14469, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8997, 16478, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8998, 17208, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8999, 17209, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (9000, 20714, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', '"Product Information. Singulair (montelukast)." Merck & Co., Inc  (2001):', 'DDInter', 0);
